Loek Eggermont

Loek Eggermont

Loek Eggermont

PhD student

Tumour Immunology Lab
RIMLS
Radboud University Nijmegen
Geert Grooteplein 28 
​6525 GA Nijmegen
The Netherlands
loek.eggermont@radboudumc.nl

Project

Active anti-cancer immune responses are dependent on efficient presentation of tumor antigens and co-stimulatory signals by antigen-presenting cells (APCs). For this purpose, natural APCs have been used in immune therapies, but isolation and culture of autologous APCs is costly, time-consuming and has resulted in variable outcomes. Therefore, development of artificial APCs (aAPCs) has gained significant interest as an alternative. We developed a new class of semi-flexible, filamentous polymers that can be decorated with T-cell activating effector molecules. These nanoworms, when conjugated to activating antibodies against CD3 and co-stimulatory molecules, are biocompatible aAPCs that can induce robust T cell responses. 

Expertise

  • Artificial antigen presentation​
  • Bio-orthogonal chemistry
  • Cancer immune therapy
  • Human T cell activation
  • Protein/antibody conjugation